Cart
sales@molnova.com
Caffeic Acid
CAS No. 331-39-5
Caffeic Acid( —— )
Catalog No. M18430 CAS No. 331-39-5
Caffeic Acid is an orally bioavailable, hydroxycinnamic acid derivative and polyphenol, with potential anti-oxidant, anti-inflammatory, and antineoplastic activities.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 100MG | 27 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCaffeic Acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionCaffeic Acid is an orally bioavailable, hydroxycinnamic acid derivative and polyphenol, with potential anti-oxidant, anti-inflammatory, and antineoplastic activities.
-
DescriptionCaffeic Acid is an orally bioavailable, hydroxycinnamic acid derivative and polyphenol, with potential anti-oxidant, anti-inflammatory, and antineoplastic activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetJNK
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number331-39-5
-
Formula Weight180.16
-
Molecular FormulaC9H8O4
-
Purity>98% (HPLC)
-
SolubilityDMSO : 106.7 mg/mL 592.25 mM
-
SMILESc1cc(c(cc1/C=C/C(=O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pradhananga S, Shim WS. Eur J Pharmacol. 2015 Sep 5;762:313-21.
molnova catalog
related products
-
J30-8
J30-8 is a subtype-selective and potent JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity for the study of neurodegenerative diseases such as Alzheimer's disease.
-
IQ3
IQ3 is a selective inhibitor of JNK3(JNK3, JNK1 and JNK2 with Kd of 66 nM, 240 nM and 290 nM, respectively).
-
AS601245.2TFA (34598...
AS601245.2TFA (345987-15-7 free base) (AS601245.2TFA) is a cell-permeable Inhibitor of JNK (IC50s of 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3, respectively).
